STROBE Statement—checklist of items that should be included in reports of observational studies

Section/item	Item No	Recommendation	Reported on Page Number/Line Number	Reported on Section/Paragraph
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	One/9	Abstract/2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	One/From 2 to 27	Abstract/From 1 to 5
Introduction				
Background/ rationale	2	Explain the scientific background and rationale for the investigation being reported	Two to three/From 32 to 63	Introduction/From 1 to 6
Objectives	3	State specific objectives, including any prespecified hypotheses	Three/From 65 to 66	Introduction/8
Methods				
Study design	4	Present key elements of study design early in the paper	Three/From 71 to 74	Methods/1
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Two/From 72 to 85	Methods/From 1 to 2
Participants	6	(a) ***Cohort study***—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up ***Case-control study***—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls ***Cross-sectional study***—Give the eligibility criteria, and the sources and methods of selection of participants	Two/From 78 to 80	Methods/2
		(b) ***Cohort study***—For matched studies, give matching criteria and number of exposed and unexposed ***Case-control study***—For matched studies, give matching criteria and the number of controls per case	N/A in the present study	N/A in the present study
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	N/A. There are not possible confounders, modifiers…	N/A. There are not possible confounders, modifiers…
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Four/From 82 to 85	Methods/ 4
Bias	9	Describe any efforts to address potential sources of bias	N/A. There are not possible	N/A. There are not possible
Study size	10	Explain how the study size was arrived at	N/A. There was not a	N/A. There was not a
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Six/From 135 to 136	Methods/5

Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	Six/From 133 to 138	Methods/9
		(b) Describe any methods used to examine subgroups and interactions	N/A as stated earlier	N/A as stated earlier
		(c) Explain how missing data were addressed	N/A. There was not missing	N/A. There was not missing
		(d) ***Cohort study***—If applicable, explain how loss to follow-up was addressed ***Case-control study***—If applicable, explain how matching of cases and controls was addressed ***Cross-sectional study***—If applicable, describe analytical methods taking account of sampling strategy	N/A as stated earlier	N/A as stated earlier
		(e) Describe any sensitivity analyses	N/A	N/A
Results				
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Six/ 141	Results/1
		(b) Give reasons for non-participation at each stage	N/A in the present study	N/A in the present study
		(c) Consider use of a flow diagram	N/A in the present study	N/A in the present study
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Six/ From 141 to 145	Results/1
		(b) Indicate number of participants with missing data for each variable of interest	Seven/From 169 to 170	Results/7
		(c) ***Cohort study***—Summarise follow-up time (eg, average and total amount)	Six/ From 141 to 142	Results/1
Outcome data	15*	***Cohort study***—Report numbers of outcome events or summary measures over time	Six/Table 3	Results/Table 3
		Case-control study—Report numbers in each exposure category, or summary measures of exposure	N/A in the present study	N/A in the present study
		Cross-sectional study—Report numbers of outcome events or summary measures	N/A in the present study	N/A in the present study
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	N/A in the present study	N/A in the present study
		(b) Report category boundaries when continuous variables were categorized	N/A in the present study	N/A in the present study
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A in the present study	N/A in the present study
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Eight/From 189 to 191	Results/Eleven
Discussion				
Key results	18	Summarise key results with reference to study objectives	Eight/From 194 to 198	Discussion/1
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Twelve/From 283 to 293	Discussion/From 15 to 17

Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Twelve/From 296 to 299	Discussion/18
Generalisability	21	Discuss the generalisability (external validity) of the study results	N/A in the present study	N/A in the present study
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	N/A in the present study	N/A in the present study

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

Article Information: https://dx.doi.org/10.21037/tau-22-108
*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.